


GSK delivers continued strong performance

"GSK's strong momentum in 2025 continues with another quarter of excellent performance driven mainly by Specialty Medicines, our largest business, with double-digit sales growth in Respiratory, Immunology and Inflammation, Oncology and HIV. We also continue to make very good progress in R&D, with 3 major FDA approvals achieved so far this year, 16 assets now in late-stage development, and 4 more promising medicines to treat cancer, liver disease and HIV expected to enter Phase III and pivotal development by the end of the year. With all this, we now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks."

Emma Walmsley
Chief Executive Officer, GSK



Specialty Medicines

£3.3bn +15%

Respiratory, Immunology and Inflammation +10%
Oncology +42%
HIV +12%

Vaccines

£2.1bn +9%

General Medicines

£2.6bn -6%

Core operating profit

£2.6bn
+12%

Total EPS

35.5p
+35%

Core EPS

46.5p
+15%

Dividend

16p

3

major new FDA product approvals so far this year

14

key opportunities expected to launch 2025-2031

16

medicines and vaccines in phase III development

4

medicines expected to enter Phase III/pivotal trials this year

Journalists/media see press release on www.gsk.com for full details on Q2 2025.
Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 59 and 60 of the press release.
Product group sales may not add to total sales due to rounding.
References to growth are at constant exchange rates (CER) unless stated otherwise.

Ahead Together